IGF-1 and ADMA Levels Are Inversely Correlated in Nondiabetic Ankylosing Spondylitis Patients Undergoing Anti-TNF-Alpha Therapy
Table 1
Partial correlation of plasma IGF-1 and IGFBP-3 with clinical characteristics and routine laboratory parameters prior to an infliximab infusion, adjusting by age at the time of the study, sex, and classic cardiovascular risk factors (dyslipidemia, smoking, obesity, and hypertension) in 30 nondiabetic patients with ankylosing spondylitis.
Variable
IGF-1
IGFBP-3
Clinical characteristics
Age at the onset of symptoms
−0.274
0.17
0.111
0.58
Disease duration*
0.353
0.07
−0.029
0.89
BMI*
−0.032
0.87
−0.191
0.34
Systolic blood pressure*
0.245
0.22
0.196
0.33
Diastolic blood pressure*
−0.012
0.95
0.192
0.34
BASDAI*
−0.044
0.83
−0.006
0.98
VAS spinal pain*
−0.119
0.55
0.169
0.40
Routine laboratory parameters
ESR* (natural-log-transformed)
−0.104
0.61
0.174
0.39
CRP* (natural-log-transformed)
−0.045
0.82
−0.111
0.58
ESR** (natural-log-transformed)
−0.033
0.87
0.108
0.59
CRP** (natural-log-transformed)
−0.008
0.97
−0.132
0.51
Total cholesterol* (natural-log-transformed)
−0.030
0.88
0.020
0.92
HDL cholesterol* (natural-log-transformed)
−0.102
0.61
−0.138
0.49
LDL cholesterol* (natural-log-transformed)
0.071
0.73
0.041
0.84
Atherogenic index* (total cholesterol/HDL)
0.102
0.62
0.161
0.43
Triglycerides* (natural-log-transformed)
−0.084
0.68
0.173
0.39
Serum glucose* (natural-log-transformed)
0.054
0.79
−0.225
0.26
At the time of the study. At the time of disease diagnosis. BASDAI: Bath ankylosing spondylitis disease activity index; BMI: body mass index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; HDL: high-density lipoprotein; IGF-1: insulin-like growth factor 1; IGFBP-3: insulin-like growth factor binding protein-3; LDL: low-density lipoprotein; VAS: visual analogue scale.
